Andres L, Iborra M, Vicente R, Arias L, et al. High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: results of a Spanish multicentre observational study. Gastroenterol Hepatol 2025;48:502379.
PMID: 39961527